23522 Federal Register / Vol. 87, No. 76 / Wednesday, April 20, 2022 / Notices 

decision of the Federal Director of 

GSA’s Office of Federal HighPerformance Green Buildings to add a 

member with specific expertise in 

environmental justice and equity. This 

decision is informed by national policy 

as reflected in Executive Order 14008, 

specifically the requirement in Section 

219 that ‘‘agencies shall make achieving 

environmental justice part of their 

missions by developing programs, 

policies, and activities to address the 

disproportionately high and adverse 

human health, environmental, climaterelated and other cumulative impacts on 

disadvantaged communities, as well as 

the accompanying economic challenges 

of such impacts’’. 

Member Responsibilities 

The individual will be appointed to a 

three-year term. Membership is limited 

to the specific individual appointed and 

is non-transferrable. All Committee 

members are expected to personally 

attend all meetings, review all 

Committee materials, and actively 

provide their advice and input on topics 

covered by the Committee. Committee 

members will not receive compensation 

but may receive travel reimbursements 

from the Government for in-person 

meetings, where a need has been 

demonstrated and funds are available. 

Request for Membership Nominations 

This notice provides an opportunity 

for individuals (or others on their 

behalf) to submit their qualifications to 

serve as a member on the Committee. 

GSA values and welcomes diversity. In 

an effort to obtain nominations of 

diverse candidates, GSA encourages 

nominations from people of all 

communities, identities, races, 

ethnicities, backgrounds, abilities, 

cultures, and beliefs, including 

underserved communities and from all 

geographic locations of the United 

States of America. 

GSA is specifically looking for 

nominees with a combination of 

professional and lived experiences and 

knowledge of environmental justice and 

equity as it relates to green buildings. 

Illustrative examples of relevant 

expertise may include: Advocacy for or 

technical assistance to communities on 

environmental justice and equity issues 

related to the built environment; 

advancing diversity, equity, inclusion 

and/or accessibility policies in 

architecture, engineering or other 

building trades; designing and/or 

operating governmental or corporate 

environmental justice and equity 

programs. 

Other criteria used to evaluate 

nominees include: 

• The background and experience 

that would help the member contribute 

to the diversity of perspectives on the 

committee (e.g., geographic, economic, 

social, cultural, educational 

background, professional affiliations, 

and other considerations); 

• demonstrated experience with 

environmental justice and community 

sustainability issues at the national, 

state, or local level; 

• excellent interpersonal and 

consensus-building skills and 

demonstrated ability to work 

constructively and effectively on 

committees. 

• ability to volunteer time to attend 

meetings 2–3 times a year, participate in 

teleconference meetings, develop policy 

recommendations, and prepare reports 

and advice letters; and 

All nominees should have at least 5 

years experience and hold academic 

degrees, certifications or training 

demonstrating knowledge in green 

building, environmental justice and 

equity. Knowledge of Federal 

sustainability and green building 

requirements, laws and programs is of 

particular value to the Committee. GSA 

will review and consider all 

applications and determine which 

candidate is likely to add the most value 

to the Committee based on the criteria 

outlined in this notice. No person 

appointed to serve in an individual 

capacity shall be a federally registered 

lobbyist in accordance with the 

Presidential Memorandum ‘‘Lobbyists 

on Agency Boards and Commissions’’ 

(June 18, 2010) and OMB Final 

Guidance published in the Federal 

Register on October 5, 2011 and revised 

on August 13, 2014. 

Nomination Process for Advisory 

Committee Appointment 

Individuals may nominate themselves 

or others. A nomination package shall 

include the following information for 

each nominee: 

(1) A letter of nomination stating the 

name and organizational affiliation(s) of 

the nominee (and position within that 

organization), nominee’s field(s) of 

expertise, specific qualifications to serve 

on the Committee, and description of 

interest and qualifications; 

(2) A professional resume or CV; and 

(3) Complete contact information 

including name, return address, email 

address, and daytime telephone number 

of the nominee and nominator. 

GSA reserves the right to choose the 

Committee member based on 

qualifications, experience, Committee 

balance, statutory requirements and all 

other factors deemed critical to the 

success of the Committee. Candidates 

may be asked to provide detailed 

financial information to ensure that the 

interests and affiliations of advisory 

committee members are reviewed for 

conformance with applicable conflict of 

interest statutes and other Federal ethics 

rules. All nominations must be 

submitted to bryan.steverson@gsa.gov 

by 5:00 p.m., Eastern Time (ET), on May 

20, 2022. 

Kevin Kampschroer, 

Federal Director, Office of Federal HighPerformance Green Buildings, Office of 

Government-Wide Policy, General Services 

Administration. 

[FR Doc. 2022–08419 Filed 4–19–22; 8:45 am] 

BILLING CODE 6820–14–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2022–N–0001] 

Science Advisory Board to the 

National Center for Toxicological 

Research Advisory Committee; Notice 

of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) 

announces a forthcoming public 

advisory committee meeting of the 

Science Advisory Board to the National 

Center for Toxicological Research. The 

general function of the committee is to 

provide advice and recommendations to 

the Agency on research being conducted 

at the National Center for Toxicological 

Research (NCTR). At least one portion of 

the meeting will be closed to the public. 

DATES: The meeting will be held 

virtually on May 18, 2022, from 8 a.m. 

to 5:55 p.m., Central Standard Time, 

and on May 19, 2022, from 8 a.m. to 

11:30 a.m., Central Standard Time. 

ADDRESSES: Please note that due to the 

impact of this COVID–19 pandemic, all 

meeting participants will be joining this 

advisory committee meeting via an 

online teleconferencing platform. 

Answers to commonly asked questions 

about FDA advisory committee meetings 

may be accessed at: https://

www.fda.gov/advisory-committees/

about-advisory-committees/commonquestions-and-answers-about-fdaadvisory-committee-meetings. The 

meeting will be webcast both days and 

will be available at the following link: 

https://fda.zoomgov.com/j/1605634800?

pwd=QWlpWUpZUnZTVnZWWUI

wckxMRVdZUT09. 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 76 / Wednesday, April 20, 2022 / Notices 23523 

Passcode: N5v5y* 

FOR FURTHER INFORMATION CONTACT: 

Donna Mendrick, National Center for 

Toxicological Research, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 32, Rm. 2208, Silver Spring, 

MD 20993–0002, 301–796–8892, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area). A notice in the 

Federal Register about last minute 

modifications that impact a previously 

announced advisory committee meeting 

cannot always be published quickly 

enough to provide timely notice. 

Therefore, you should always check the 

Agency’s website at https://

www.fda.gov/AdvisoryCommittees/

default.htm and scroll down to the 

appropriate advisory committee meeting 

link, or call the advisory committee 

information line to learn about possible 

modifications before coming to the 

meeting. 

SUPPLEMENTARY INFORMATION: 

Agenda: On May 18, 2022, the 

Science Advisory Board Chair will 

welcome the participants, and the NCTR 

Director will provide a Center-wide 

update on scientific initiatives and 

accomplishments during the past year. 

The Science Advisory Board will be 

presented with an overview of the 

Science Advisory Board Subcommittee 

Site Visit Report and a response to this 

review. The Center for Biologics 

Evaluation and Research, Center for 

Drug Evaluation and Research, Center 

for Devices and Radiological Health, 

Center for Food Safety and Applied 

Nutrition, Center for Tobacco Products, 

and the Office of Regulatory Affairs will 

each briefly discuss their specific 

research strategic needs and potential 

areas of collaboration. 

On May 19, 2022, there will be 

updates from the NCTR Research 

Divisions and a public comment 

session. Following an open discussion 

of all the information presented, the 

open session of the meeting will close 

so the Science Advisory Board members 

can discuss personnel issues at NCTR. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its website prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s website after 

the meeting. Background material is 

available at https://www.fda.gov/ 

AdvisoryCommittees/Calendar/

default.htm. Scroll down to the 

appropriate advisory committee meeting 

link. 

Procedure: On May 18, 2022, from 8 

a.m. to 5:55 p.m., Central Standard 

Time, and May 19, 2022, from 8 a.m. to 

11:30 a.m., Central Standard Time, the 

meeting is open to the public. Interested 

persons may present data, information, 

or views, orally or in writing, on issues 

pending before the committee. Written 

submissions may be made to the contact 

person on or before May 13, 2022. Oral 

presentations from the public will be 

scheduled between approximately 1 

p.m. and 2 p.m. Central Standard Time. 

Those individuals interested in making 

formal oral presentations should notify 

the contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before May 5, 2022. Time allotted for 

each presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by May 6, 2022. 

Closed Committee Deliberations: On 

May 19, 2022, from 11:30 a.m. to 12 

p.m., Central Standard Time, the 

meeting will be closed to permit 

discussion where disclosure would 

constitute a clearly unwarranted 

invasion of personal privacy (5 U.S.C. 

552b(c)(6)). This portion of the meeting 

will be closed to permit discussion of 

information concerning individuals 

associated with the research programs at 

NCTR. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

Agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with disabilities. 

If you require accommodations due to a 

disability, please contact Donna 

Mendrick at least 7 days in advance of 

the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our website at 

https://www.fda.gov/Advisory

Committees/AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: April 15, 2022. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2022–08460 Filed 4–19–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2021–D–1155] 

The Use of Published Literature in 

Support of New Animal Drug 

Applications; Draft Guidance for 

Industry; Availability 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of availability. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

announcing the availability of a draft 

guidance for industry #106 entitled 

‘‘The Use of Published Literature in 

Support of New Animal Drug 

Applications.’’ This draft guidance, 

when finalized, will replace the existing 

final guidance #106, ‘‘The Use of 

Published Literature in Support of New 

Animal Drug Approval,’’ which FDA 

published in August 2000 and which 

specifically addressed the use of a single 

article to support drug approval. This 

revision of the guidance document 

considers multiple uses of the scientific 

literature, including narrative reviews, 

systematic reviews, and meta-analyses 

to support approval of a new animal 

drug. 

DATES: Submit either electronic or 

written comments on the draft guidance 

by June 21, 2022 to ensure that the 

Agency considers your comment on this 

draft guidance before it begins work on 

the final version of the guidance. 

ADDRESSES: You may submit comments 

on any guidance at any time as follows: 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 


khammond on DSKJM1Z7X2PROD with NOTICES